Ethics of placebo-controlled clinical trials in multiple sclerosis
C. H. Polman(National Multiple Sclerosis Society), Jerry S. Wolinsky(The University of Texas Health Science Center at Houston), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Gary Cutter(Alabama Department of Public Health), M. S. Freedman(National Multiple Sclerosis Society), Brian G. Weinshenker(Mayo Clinic in Arizona), Stephen C. Reingold(Clinical Research Associates), Ludwig Kappos(Novartis (Switzerland)), Hillel Panitch(University of Vermont), Peter A. Calabresi(Johns Hopkins University), Maria Pia Sormani(University of Genoa), Frederik Barkhof(Netherlands Institute for Neuroscience), Alan J. Thompson(Queen Mary University of London), J Richert(National Multiple Sclerosis Society), John Petkau(National Multiple Sclerosis Society), Luanne M. Metz(University of Calgary), Paul O’Connor, Jeffrey A. Cohen(Cleveland Clinic), Aaron E. Miller(Icahn School of Medicine at Mount Sinai), S. R. Schwid(National Multiple Sclerosis Society), Fred Lublin(Icahn School of Medicine at Mount Sinai), H. F. McFarland(National Multiple Sclerosis Society), Michel Clanet(National Multiple Sclerosis Society)
Cited by 73
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k